Price History

Hover for the daily close. The dotted line marks the period open.

Compare RNAC with… →

RNAC Key Statistics

As of Sep 4, 2026

Trading

Open: $9.12
Previous Close: $9.12
Day's Range: 8.89–9.31
52-Week Range: 5.60–11.00
Volume: 68.40K
Beta: 0.62

Valuation

Market Cap: $280.47M
P/E Ratio: unprofitable
P/S ratio: 189.89
EPS (ttm): −5.89

Financials (FY)

Revenue (FY): $2.80M−92.81%
Net Income (FY): −$130.30M
Profit margin: 0.00%
Shares Outstanding: 30.26M
1-Year Return: −7.30%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 254.24K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RNAC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+53.61%−72.88%+28.57%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+28.57%
2025	−59.74%
2024	−13.35%
2023	−39.03%
2022	−65.34%
2021	+7.59%
2020	+27.31%
2019	−10.53%
2018	−72.88%
2017	−42.80%
2016 (partial year)	+53.61%

As of September 4, 2026.

RNAC Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$2.80M	−$130.30M	−4658.6%
2024	$38.91M	−$77.42M	−199.0%
2023	$26.00M	−$219.71M	−844.9%
2022	$110.78M	$35.38M	31.9%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$2.80M	—	−$86.71M	−$130.30M	−4658.6%
2024	$38.91M	—	−$36.32M	−$77.42M	−199.0%
2023	$26.00M	—	−$85.71M	−$219.71M	−844.9%
2022	$110.78M	—	$14.54M	$35.38M	31.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RNAC Valuation vs Biotechnology Median

Median of 656 stocks

Metric	RNAC	Biotechnology median	vs median
P/S ratio	189.89	15.26	12.4x the median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cartesian Therapeutics, Inc. (RNAC) is capitalised at $280.47M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 75 employees.

Over the past 52 weeks the price has ranged from $5.60 to $11.00. RNAC last closed at $9.27 on September 4, 2026. That is +$0.15 (+1.64%) against the previous close. The latest close sits 65.54% above that 52-week low.

Financial Health

In fiscal 2025, Cartesian Therapeutics, Inc. reported revenue of $2.80M. Against the prior fiscal year total of $38.91M, that is a change of −92.81%. The same year closed with a net loss of $130.30M. The reported profit margin is 0%. Trailing earnings per share are −5.89.

Across the 4 fiscal years on file, revenue moves from $110.78M in 2022 to $2.80M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 189.89 times revenue. On price-to-sales that is 12.4 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −7.30%. Across 10 years the annualized return works out at −30.56%. Beta against the wider market is reported at 0.62. Annualized volatility over the trailing 10 years is 90.91%.

Growth & Income

The record shows no dividend for RNAC.

2026 is still running; the price is +28.57% year to date. Across the complete calendar years on file, 2020 returned +27.31% and 2018 returned −72.88%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Cartesian Therapeutics, Inc. (RNAC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Cartesian Therapeutics, Inc.	RNAC	$280.47M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Cartesian Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Visit website →

Cartesian Therapeutics, Inc. (RNAC) Stock Analysis